NCAPGP2

Across TCGA pan-cancer cohorts, NCAPGP2 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated NCAPGP2 data layer.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher NCAPGP2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated NCAPGP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and SARC show a favorable association.

PAAD, CHOL, and BRCA are the cancer types where NCAPGP2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Tertile	All	0.215	0.563	<.001	54	view →
CHOL	OS	Tertile	III,IV	0.024	0.772	.008	54	view →
BRCA	OS	Tertile	IV	0.233	0.755	.038	36	view →
READ	DFS	Tertile	IV	0.055	0.646	<.001	36	view →
PRAD	DFS	Tertile	All	0.820	0.943	<.001	30	view →
MESO	OS	Tertile	IV	0.155	0.624	.004	27	view →
LIHC	OS	Tertile	III,IV	0.310	0.694	<.001	15	view →
THCA	OS	Quartile	All	0.944	0.990	.007	8	view →
LUAD	OS	Median	III,IV	0.398	0.225	.009	8	view →
BLCA	DFS	Tertile	III,IV	0.408	0.561	.042	6	view →
OV	OS	Median	IV	0.674	0.811	.020	6	view →
STAD	DFS	Quartile	All	0.167	0.531	.009	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

NCAPGP2–PAAD (OS)

Open the PAAD breakdown →